Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | HTR2C | P28335 | 2/20 | 0.58 |
| ▸ | HTR2B | P41595 | 2/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462272 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13862057 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL815202 | 0.81 | SLC6A2 (1.00) | SIGMAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL814759 | 0.81 | SLC6A2 (1.00) | SIGMAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL815021 | 0.81 | SLC6A2 (1.00) | SIGMAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL814198 | 0.81 | SLC6A2 (1.00) | SIGMAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL815201 | 0.81 | SLC6A2 (1.00) | SIGMAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL53985 | 0.80 | CYP2C19 (0.74) | SIGMAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9731285 | 0.78 | SIGMAR1 (0.68) | SIGMAR1CYP2C19CYP3A4MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL9732394 | 0.77 | SIGMAR1 (0.67) | SIGMAR1CYP2C19CYP3A4MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TEMPLE OTORONGO LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-20210275623-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | OPRK1, TPH1, HTR3C | SIGMAR1 200/4885CYP2D6 591/4885SLC6A2 128/4885 |
| US-20210275623-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TPH1, TPH2, SYMPK | SIGMAR1 978/4885CYP2D6 1606/4885SLC6A2 276/4885 |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TPH1, TPH2, SYMPK | SIGMAR1 978/4885CYP2D6 1606/4885SLC6A2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.